Rigel Pharmaceuticals (RIGL) Non-Current Assets (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Non-Current Assets of $270.6 million for Q1 2026, up 820.06% year-over-year from $29.4 million in Q1 2025, and down 1.04% quarter-over-quarter from $273.4 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Non-Current Assets (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $270.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 820.06% year-over-year to $270.6 million; the TTM figure through Mar 2026 stood at $603.0 million (up 382.68% YoY), while the FY2025 annual figure was $273.4 million, up 847.0% from the prior year.
- Non-Current Assets for Q1 2026 stood at $270.6 million, down from $273.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $273.4 million in Q4 2025, with the low at $5.2 million in Q3 2022.
- The 5-year median for Non-Current Assets is $27.6 million (2025), against an average of $51.4 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets slumped 66.47% in 2022, then jumped 847.0% in 2025.
- Rigel Pharmaceuticals' Non-Current Assets stood at $18.4 million in 2022, then dropped by 2.27% to $18.0 million in 2023, then jumped by 60.77% to $28.9 million in 2024, then surged by 847.0% to $273.4 million in 2025, then slipped by 1.04% to $270.6 million in 2026.
- Business Quant data shows RIGL's Non-Current Assets at $270.6 million in Q1 2026, $273.4 million in Q4 2025, and $27.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 335.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 335.54 Mn |
| Mar 31, 2026 | 270.58 Mn |
| Dec 31, 2025 | 273.43 Mn |
| Sep 30, 2025 | 27.61 Mn |
| Jun 30, 2025 | 31.34 Mn |
| Mar 31, 2025 | 29.41 Mn |
| Dec 31, 2024 | 28.87 Mn |
| Sep 30, 2024 | 32.95 Mn |
| Jun 30, 2024 | 33.69 Mn |
| Mar 31, 2024 | 34.03 Mn |
| Dec 31, 2023 | 17.96 Mn |
| Sep 30, 2023 | 20.30 Mn |
| Jun 30, 2023 | 16.17 Mn |
| Mar 31, 2023 | 16.64 Mn |
| Dec 31, 2022 | 18.38 Mn |
| Sep 30, 2022 | 5.17 Mn |
| Jun 30, 2022 | 7.48 Mn |
| Mar 31, 2022 | 10.14 Mn |
| Dec 31, 2021 | 12.86 Mn |
| Sep 30, 2021 | 15.41 Mn |